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Reduced crystallization inhibition by urine from men with understood to arise mainly from the nondialyzable mole-
nephrolithiasis. cules of urine, particularly acidic glycoproteins, and gly-
Background. Human urine is known to inhibit growth, ag- cosaminoglycans [2–4]. Some inhibitor molecules havegregation, nucleation, and cell adhesion of calcium oxalate
been identified, including Tamm Horsfall protein [5],monohydrate (COM) crystals, the main solid phase of human
uropontin [6, 7], calgranulin [8], bikunin [9], and pro-kidney stones. This study tests the hypothesis that low levels
of inhibition are present in men with calcium oxalate stones thrombin F1 fragment [10]. Despite clear evidence of
and could therefore promote stone production. urine inhibition and at least some well-defined molecules
Methods. In 17 stone-forming men and 17 normal men that that account for inhibition, we lack a strong clinical linkwere matched in age to within five years, we studied the inhibi-
between reduced inhibition and stone pathogenesis, andtion by dialyzed urine proteins of COM growth, aggregation,
inhibition measurements play no role in the clinical prac-and binding to cultured BSC-1 renal cells, as well as whole urine
upper limits of metastability (ULM) for COM and calcium tice of medical stone evaluation or prevention [11, 12].
phosphate (CaP) in relationship to the corresponding supersat- Perhaps one reason for the lack of clinical linkage is
uration (SS). the paucity and narrowness of studies that test whetherResults. Compared with normals, patient urine showed re-
such linkages actually exist. Two of our studies conflict.duced COM growth inhibition and reduced ULM in relation-
One showed reduced CaOx crystal growth inhibition inship to SS. When individual defects were considered, 15 of the
17 patients were abnormal in one or more inhibition measure- stone formers as compared with normal urine [13]. A
ments. ULM and growth inhibition defects frequently coex- second, which focused on only patients with extremely
isted. active disease [14], showed no such link. A third studyConclusions. Reduced COM growth and CaP and CaOx
linked abnormal aggregation inhibition to possible de-ULM values in relationship to SS are a characteristic of male
stone formers. Both defects could promote stones by facilitat- fects of Tamm Horsfall protein, but patients were few [5].
ing crystal nucleation and growth. Abnormal inhibition may Tiselius et al compared CaOx growth and aggregation
be a very important cause of human nephrolithiasis. inhibition in normals and stone formers [15]. They found
reduced aggregation inhibition in stone formers of both
sexes and reduced growth inhibition in only the male
The pathogenesis of calcium renal stones for many stone formers. Pak et al in a group of studies showed
years has been described in terms of diseases and inher- a reduced threshold for CaOx and CaP nucleation, as
ited traits that increase urine supersaturation (SS) with measured by the upper limit of metastability (ULM)
respect to the common stone-forming salts, calcium oxa- [16–19]. We have found traces of the same phenomenon,
late (CaOx), calcium phosphate (CaP), uric acid, cystine, although less marked, among a group of unselected pa-
and struvite [1]. At the same time, all workers in the tients, but also found that ULM varied with SS so that
field are aware that human urine strongly modulates and no one value of ULM could define a normal range, but
kinetically delays nucleation, growth, and aggregation of only the relationship between ULM and SS [20]. Hess
at least CaOx and CaP [2, 3]. The inhibition is generally et al [5, 21] and others [15, 22] have found a reduced
urine ability to delay CaOx crystal aggregation among
stone formers, but whether or not this is a systematicKey words: renal stones, calcium oxalate, upper limit of metastability,
crystal growth. trait of patients or a sporadic finding is not clear. Older
studies using less well-defined assays also have suggestedReceived for publication November 25, 1998
reduced urine inhibition among stone formers [23–25].and in revised form April 16, 1999
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pathogenesis, clinical assays of inhibition are not used above trace, no family history of stones, no systemic
or renal disease ever diagnosed, and were taking noin medical practice. By contrast, urine chemistries that
regulate SS and measurements of SS itself are common medications that either would suggest systemic or renal
disease or that could influence mineral metabolism. Forproducts for patient care and a guide to medical preven-
tion [4, 11, 12]. two patients of Hispanic origin and one of Chinese origin,
we found race-matched normals.We do not believe that with this one study we can
alter the practice of medicine nor define the single best Prior to this research, each patient was studied using
three 24-hour urines, each with a corresponding bloodassay for guiding research, but we have attempted to
place a number of inhibition measurements in proper sample drawn between 7 and 9 a.m. in the postabsorptive
state. From this inquiry and using these criteria, we foundrelationship to each other in regard to their ability to
distinguish normal men from stone-forming men. We metabolic abnormalities as follows: urine calcium above
140 mg/g creatinine [29], 9; urine citrate below 325 mg/reasoned that a test able to discriminate normal from
abnormal probably registers some difference that is im- day, 8; urine oxalate above 50 mg/day, 6; urine uric acid
above 800 mg/day, 5. Of these, eight patients had onlyportant in producing stones and can guide at least future
clinical investigation of the mechanisms of inhibition, the one abnormality (3 calcium, 5 citrates). Two patients had
two abnormalities (calcium and uric acid, uric acid andmolecules responsible, and the causes of the abnormal
conditions that cause stones. This study was restricted oxalate). Four patients had three abnormalities (calcium
and oxalate and citrate, N 5 2; and calcium, uric acid andto male CaOx stone formers; they were compared with
age-, sex- and race-matched controls, and the urine inhi- oxalate, N 5 2). One patient had four abnormalities and
two patients had no abnormalities.bition of nucleation, growth, aggregation, and crystal-to-
cell adhesion for CaOx were measured, asking which,
Laboratory studiesif any, of these measurements give a clear distinction
between patients and normals. Our single-sex population Conventional studies and preparation of dialyzed urine
proteins. For each patient and normal, we obtained ais a choice based on our many observations showing that
abnormalities related to stone disease in men and women 24-hour urine for the measurement of established stone
risk factors: calcium, oxalate, citrate, phosphate, pH,differ extremely, and each require a protocol [26–28].
magnesium, and uric acid. To calculate SS, we also mea-
sured sulfate, ammonium ion, chloride, potassium, and
METHODS
sodium. Urine creatinine was measured to assess the
Patients and controls completeness of collection. Each patient was also evalu-
ated clinically prior to entering this research protocolWe randomly selected 17 men with at least two sepa-
rate new stone episodes and whose stones proved to be using three 24-hour urines, each with a corresponding
serum sample, as we have described elsewhere [26].principally CaOx, and none of whose stones had ever
contained uric acid, cystine, or struvite. The number of These results, not reported here, were used in conjunc-
tion with medical history, stone analyses, and all priorstones per patient ranged from a low of 2 to a high of
over 100. The time from the first stone to entering our radiographs relevant to stones to ascertain clinical classi-
fication, as noted earlier in this article, and to guideprogram ranged from 2 months to 15 years. This wide
spread is usual in samples of calcium stone formers. No treatment.
A 100 ml aliquot of the urine collected for this researchpatient had stones from a systemic disease, including
primary hyperparathyroidism, sarcoidosis, vitamin D ex- was dialyzed using a 3500 Dalton membrane at 48C for
48 hours against 10 mm NaCl, 5 mm Tris, pH 7.2, withcess, bowel disease of any kind, renal tubular acidosis,
or primary hyperoxaluria. As well, we excluded patients two changes of the bath. In one experiment, a second
aliquot of one urine was dialyzed in exactly the samewith dipstick proteinuria above trace and any patients
with diabetes because we wished to avoid renal disease. manner but against distilled water. The protein concen-
tration was measured by the ninhydrin method [30]. IfNone had a serum creatinine level above 1.25 mg/dl, and
none had hereditary or acquired anatomical disorders the urine proteins were too dilute to be used in the
assays, the sample was concentrated and the proteinof the kidney or the urinary drainage system. For patients
on medications that could affect stones or mineral metab- concentration remeasured. This protein mix was used for
the assays of growth and aggregation and cell adhesionolism, medications were discontinued one week before
the 24-hour urines were obtained. We did not alter the inhibition. SS for CaOx and CaP was calculated using
EQUIL 2 [31].diet from what was in effect at the time of this study.
Our program specifically avoids low-calcium diets, and Upper limits of metastability. A modification of the
method described by Nicar, Hill, and Pak was used totherefore, no patient was knowingly placed on such a
diet. For each patient, a normal subject within five years determine the ULM of CaOx and brushite (Br) in human
urine as previously described from this laboratory [17,of age was found. Normals had no dipstick proteinuria
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20, 30]. An aliquot of urine from a 24-hour urine collec- addition were studied if needed to ensure that the range
of measurements included the 50% growth inhibitiontion was centrifuged for 30 minutes at 3000 r.p.m. to
remove debris. Urine pH was adjusted to 6.4 by the point. To test the effects of water versus buffer dialysis,
the percentage inhibition of the water-dialyzed aliquotaddition of HCl or NaOH as required. Ten milliliters of
each urine sample were placed into each of 13 tubes, versus buffer-dialyzed aliquot of urine from a single nor-
mal subject was measured. Values were 38.2 versus 48.5%and sodium azide was added to each tube at a final
concentration of 0.02% to prevent bacterial growth. The of control, buffer versus water.
CaOx crystal aggregation. COM crystal slurries 0.8tubes were placed in a water bath at 378C and magneti-
cally stirred. To initiate CaOx precipitation, increasing mg/ml (average crystal diameter of 2 to 5 mm) were
prepared in 10 mm acetate, pH 5.7, were equilibratedamounts of sodium oxalate were added to each set of
tubes. One tube had no oxalate added to serve as blank. overnight at 378C, and were magnetically stirred at 1100
r.p.m. The crystals and solution come to equilibrium soThe pH of each tube was checked hourly during the
incubation, and 1 m HCl or 1 m NaOH was added as that crystals no longer dissolve or grow. The slurry was
then pipetted into multiple tubes, each used for a singlerequired to maintain the pH at 6.4. The total volume of
additions was always below 1% of the total volume of assay. Urine protein samples were added to the stirred
slurries 30 minutes prior to assay. A 2 ml aliquot ofurine in each tube. After three hours, the samples were
checked for visible precipitation; the tube with the lowest the crystal slurry was transferred to a quartz cuvette
maintained at 378C and was constantly monitored at 620amount of oxalate added that initiated crystallization
was considered the endpoint. The SS at the point of nm. In this system, OD620 is proportional to the mass of
crystal per unit volume [33]. The slurry was initiallyprecipitation was calculated using EQUIL2, assuming
all chemical concentrations were unchanged except for stirred at 1100 r.p.m. to obtain a stable baseline, and
then crystal aggregation was induced by slow stirring atoxalate, which was taken as the initial measured oxalate
concentration plus the amount added to the tube. ULM 500 r.p.m. for 170 seconds. Stirring was stopped, and
particle sedimentation was monitored. The rate of fallfor CaP was determined in the same fashion, except
calcium chloride was added to the urine samples to pre- in OD620, measured as the slope of the straight portion
of the plot of OD versus time, reflects the average parti-cipitate CaP, which is known to be in the form of Br
under these conditions [17]. cle size and is taken as a measure of aggregation [33].
The assay was run with and without the urine proteinsCaOx crystal growth inhibition. CaOx monohydrate
(COM) crystal seed slurries (0.8 mg/ml) were prepared in an alternating fashion such that each urine sample
was sandwiched by control measurements. The resultsby the addition of 8 mg of COM crystal (average diame-
ter 2 to 5 mm) to 10 ml of 90 mm NaCl, 10 mm Tris for the protein samples are expressed as a percentage
of the sedimentation rate of the controls. Urine proteinbuffer, pH 7.2. The slurry was mixed with a magnetic
stirrer overnight at 1100 r.p.m. The seed slurry was added was added to the assay at fixed percentages of the 24-
hour urine protein excretion, specifically 0.002, 0.006,to 2 ml of a metastable CaOx solution consisting of 0.5
mm Ca, 0.5 mm oxalate, 90 mm NaCl, 10 mm Tris, pH and 0.012%, and duplicates were run at each protein
level. Additional levels of protein addition were studied7.2, contained in a quartz cuvette, 378C, and magnetically
stirred at 1100 r.p.m. Oxalate consumption was initiated if needed to ensure that the range of measurements in-
cluded the 50% aggregation inhibition point. To test theby the addition of seed crystals and was monitored for
400 seconds with a continuous-recording spectropho- effects of water versus buffer dialysis, we measured the
percentage of inhibition of the water-dialyzed aliquottometer at 214 nm. Data were collected using a Lambda
7 spectrophotometer (Perkin Elmer Corp., Norwalk CT, versus buffer-dialyzed aliquot of urine from a single nor-
mal subject. Values were 41.6 versus 54.0% of control,USA) interfaced to a personal computer by a data-acqui-
sition system (Lakeshore Technologies, Chicago, IL, buffer versus water.
Adhesion of CaOx crystals to renal cells. Crystal bind-USA). The rate of oxalate consumption follows second-
order kinetics, and from the integrated rate equation, ing to renal epithelial cells of the nontransformed Afri-
can green monkey line BSC-1 was assayed as previouslywe derive the velocity of the reaction [32]. The assay was
run with and without the urine proteins in an alternating described [34]. High-density, quiescent cultures were
prepared by plating 2 3 106 cells per 60 mm dish (Nunc,fashion such that each urine sample was sandwiched by
control measurements. Results for the protein samples Naperville, IL, USA) in Dulbecco-Vogt–modified Ea-
gle’s medium containing 25 mm glucose (DMEM), 1%are expressed as a percentage of the reaction velocity of
the controls, such that greater inhibition will result in calf serum, and 1.6 mm biotin (E 1 1%); cultures were
maintained at 388C in a CO2 incubator. The spent me-smaller reaction velocities and a lower percentage of
control. Urine protein was added to the assay at fixed dium was changed after three days so that there were 3
to 4 3 106 cells per plate six days later. Then the mediumamounts of 8, 16, and 32 mg, and duplicates were run at
each protein concentration. Additional levels of protein was aspirated and replaced with fresh medium containing
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0.01% calf serum and 16 mm biotin; three days later, the among patients, as is usually found [11]. Oxalate and
citrate are remarkably similar, as are urine volumes. Thequiescent cultures were used for study.
To measure crystal adhesion, BSC-1 cell culture me- lack of distinctive hypocitraturia among male patients
versus normal men is exactly as we have shown in thedium was aspirated and replaced with 5 ml of phosphate-
buffered saline (PBS) at 378C, to which dialyzed urine past [26]. In addition to these excretion rates, concentra-
tions of calcium, oxalate, phosphorus, and citrate alsoprotein was added to achieve a final concentration of 50
or 100 mg/ml. [14C]COM crystals, prepared as previously did not differ between patients and normals (data not
shown).described [34], were added to the buffer to achieve a
final concentration of 200 mg/ml (47.2 mg/cm2 of cells). Among normals, SS and ULM (Fig. 2) were correlated
for CaP (Fig. 2A) and CaOx (Fig. 2B), as we have shownThe culture dishes were gently agitated for five seconds
to distribute uniformly the crystals that then settled to in the past in a less stringent protocol [20] and among
hypercalciuric rats (r 5 0.84, P 5 0.0001 for CaP andthe surface of the cell monolayer under the force of
gravity. After two minutes, the buffer was aspirated, and r 5 0.68, P 5 0.017 for CaOx) [30]. By contrast, among
patients, correlations were not significant (r 5 0.29 forthe cells were washed three times with PBS (5 ml). The
cells were then scraped directly into a scintillation vial CaP and r 5 0.46 for CaOx, P 5 NS for both). The mean
values for SS and ULM did not differ between patientscontaining 6 N HCl (0.5 ml), to which 4.5 ml of Ecoscint
and controls (8.3 vs. 10.4 and 1.31 vs. 1.75, for SS CaOx(National Diagnostics, E. Palmetto, FL, USA) were
and SS CaP, normal vs. patient; 4.2 vs. 3.7, and 20 vs.added, and the amount of radioactivity was measured
20, for ULM CaP and CaOx, normals vs. patients, respec-[35]. The protein concentrations used were in the region
tively; all P values 5 NS). However, when the differenceof greatest sensitivity of the assay (data not shown).
of ULM CaP between normals and patients was tested
Analysis using analysis of variance with SS CaP as covariate, the
P value fell from 0.22 by t-test to 0.055, the latter notRoutine t-tests and nonparametric estimates were used
quite significant but suggestive. For CaOx, such an analy-to test differences between patients and normals. When
sis made no difference (P values were 0.86 and 0.54,inhibition assays used varying amounts of added pro-
respectively).teins, differences were tested by analysis of covariance.
As we have reported before, patients and normalsThe homogeneity of slopes was tested using the P value
maintained a good distance between ULM and SS forfor the interaction term of group by protein added. When
both CaOx and CaP, as shown by the gap between eachslopes were heterogeneous, the interaction term was re-
point and the diagonal lines of identity on the left andmoved from the final model. The same was used to test
center panels of Figure 2. However, patient points forULM differences, except that SS was the covariate. In
ULM CaP show a tendency to droop downward, towardsome bivariate displays, kernel density estimators were
the line. Seven of the 17 patients have ULM values closerused to outline the principle concentrations of points
to the line than any of the 17 normal subjects. For ULMfrom patients versus normals. All statistical calculations
CaOx, patient points tram track into two roughly parallelwere performed using Systat software (Systat Inc., Chi-
groups, one indistinguishable from normals, the othercago, IL, USA)
distinctly lower. The two groups are divided by a line of
normal points that runs between them, diagonally up-
RESULTS ward from the lower left to the upper right of the graph.
None of the 12 conventional measurements used to If the difference between ULM and SS for CaP is
assess stone-forming risk (Fig. 1) nor urine creatinine plotted against the corresponding difference for CaOx
(data not shown) differed between normals and patients (Fig. 2C), normal values cluster in a small space, outlined
using t-tests, even when we relaxed the correction for by the 85% nonparametric smoother. Patient points
multiple significance testing. The boxes narrow to a waist spread out over much of the graph surface. They split into
at the median value, and their notched areas enclose two elongate lobes along the CaOx axis, representing the
the 95% nonparametric confidence limits, which overlap, two tram tracks in the Figure 2B. Within each lobe,
indicating a lack of significant difference, for all tests points droop downward, reflecting the left hand panel.
except urine calcium. In contrast to t-tests, the nonpara- What seems a best summary of the data is a coherent and
regular behavior of ULM in relationship to SS amongmetric notch boxes document higher urine calcium
c
Fig. 1. Notched box plots of standard urine stone risk factors. Abbreviations are: MN, male normals; MSF, male stone formers. MSF did not
differ in regard to any measurement by t-test. All values are 24-hour urine in milligrams except for volume (liters), sodium potassium sulfate
ammonium ion 2 mEq. Notches of bars represent 95% confidence limits, which overlay between MN and MSF in all cases.
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Fig. 2. Upper limit of metastability (ULM) and supersaturation (SS) values. Values of ULM versus SS for CaP (A) and CaOx (B) for normals
(s) and patients (d) are all above the diagonal lines of identity with four exceptions. The ULM to SS difference (C) for normals is clustered in
a small area (open circles) compared with the split and dispersed patient data.
Fig. 3. Effects of urine citrate on the upper
limit of metastability (ULM) values. ULM
CaP ( y axis, A) rises with urine citrate concen-
tration (x axis). Values of the regression coef-
ficients are significant for both patients (d)
and normals (s) (0.601 and 0.380; P 5 0.023
and 0.011, respectively).
normals that is not at all present among patients, whose independent correlation (r 5 0.56, P 5 0.02 for patients,
and r 5 0.81, P 5 0.0001 for normals). In other words,data spread more, and in whom ULM does not track SS
accurately. urine citrate concentration is an important modifier of
the ULM and, as such, may act as a defense against stones.We have concentrated on a presentation of ULM
against SS because the distance of their separation is a Despite the dominant influence of urine citrate con-
centration on ULM (Fig. 3), when ULM for CaP andgauge of the risk for crystal nucleation. However, among
all of the excretions (Fig. 1) and concentrations (data CaOx of patients and normals was compared, with citrate
concentration as covariate, the groups did not differ.not illustrated) in urine, ULM CaP correlated best with
urine citrate (r 5 0.60, P 5 0.023) and calcium concentra- This is illustrated by the overlap of points (Fig. 3) and
by the P values for the analysis of covariance: The meantions (r 5 0.38, P 5 0.026) in patients and with urine
citrate concentration (r 5 0.38, P 5 0.011) and SS CaP ULM CaP values adjusted for citrate and calcium con-
centration were 3.7 versus 4.2 (P 5 0.08); the mean ULM(r 5 0.45, P 5 0.046) in normals. All coefficients and
P values are from multiple linear regression. Although CaOx values adjusted for citrate, its only independent
covariate, were 20.4 versus 19.1 (P 5 0.33, both patientULM had an independent correlation with urine pH,
once the effects of calcium and citrate were removed, vs. normal). The slopes were not different between patients
and normals. Because patient and normal values for ci-pH no longer had a residual influence (P 5 0.067). For
ULM CaOx, only the urine citrate concentration had an trate concentration overlap greatly, the effects of citrate,
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Fig. 4. Three measures of inhibition. (A) CaOx crystal growth inhibition. Inhibition is plotted as mean 6 sem percentage control growth, against
micrograms of dialyzed urine protein per flask for 2, 8, 16, 32, 48, and 64 mg. Values differed at 8, 16, 32, and 48 mg/flask: 74 vs. 66, 60 vs. 54, 47
vs. 38, and 40 vs. 25, normal vs. patient, P 5 0.029, 0.013, 0.0001, and 0.0001, respectively, for the four concentrations. (B) CaOx crystal aggregation
inhibition. Aggregation is plotted in units of percentage control against micrograms of dialyzed urine protein per flask for patients (d) and normals
(s). The regression slopes for patients (solid line) and normals (dashed line) were not different. (C) CaOx adhesion to cultured BSC-1 renal cells.
The adhesion in the presence of 100 mg/flask of total urine protein was not different for patients (d) and normal subjects (s), although the values
from patients were slightly higher as shown by the box plots. The individual points and the smoothed frequency distributions of values to either
side overlap.
although powerful, do not explain differences in the normal, P 5 0.15 and 0.35). When normal versus patient
was tested using analysis of variance with the covariateULM or the ULM to SS distance between patients and
normal. being protein added to each flask expressed as a percent-
age of original concentration in the urine (not shown),Calcium oxalate crystal growth inhibition by patient
proteins was impressively reduced compared with nor- the slopes differed significantly (2112 vs. 247, patient
vs. normal, P 5 0.02 for difference of slopes), indicatingmal (Fig. 4A). At each of the four central protein concen-
trations, 8, 16, 32, and 48 mg/flask, normal values were a greater proportional reduction of aggregation with in-
creasing protein concentration among patients comparedsignificantly lower (means and t-tests in Fig. 4).One po-
tential problem with this analysis is that urine protein with normals. When the protein added was expressed as
a percentage of the 24-hour excretion (not shown), slopesexcretion and concentration of patients and normals,
although not significantly different (308 mg/24 hr vs. 268 also differed significantly (21405 vs. 2626, patient vs.
normal, P 5 0.03). When protein is expressed as micro-mg/24 hr, excretions, and 199 mg/liter vs. 185 mg/liter,
concentrations, patient vs. normal, P 5 0.13 and 0.57, gram per flask (Fig. 4B) and normal versus patient is
tested by analysis of variance with protein as covariate,respectively), were nevertheless not identical. Using
analysis of variance with the percentage of 24-hour pro- the difference is not significant (56 vs. 61%, patient vs.
normals, P 5 0.47), and the slopes of their regressionstein as a covariate, the patient and normal differed at
high significance (adjusted means 56 vs. 51, patients vs. do not differ (P 5 0.51 for homogeneity of slopes). Put
another way, if we adjust for protein additions as thenormals, P 5 0.004). When added protein is expressed
as a percentage of the initial urine protein concentration, percentage of 24-hour excretion or the percentage of
original urine concentration, the inhibition of aggrega-the significance remains about the same (adjusted means
56 vs. 50, patient vs. normal, P 5 0.002). No matter how tion by patient proteins surpasses that of normal pro-
teins. The same trend is present by simple t-tests of thewe adjust for protein amounts, growth inhibition always
differed between patients and normals, the patients in- three fixed-percentage 24-hour urine values, but is not
significant except for the lowest addition. Overall, aggre-hibiting less.
By contrast, CaOx crystal aggregation inhibition by gation and growth inhibition differ. For aggregation, the
results are not completely consistent, and normal urinepatient proteins differed from normal more variably and
with patients having the stronger inhibition effect. We seems to inhibit less well than urine from patients. For
growth, results are highly consistent, and normal urineadded proteins to the assay at 0.002, 0.006, and 0.012% of
the 24-hour excretion rate. At the lowest point, 0.002%, inhibits far more effectively than urine from patients.
The inhibition of CaOx crystal adherence to culturedpatient and normal values differed (66 vs. 73 patients vs.
normals, P 5 0.04). At the other two concentrations, renal cells did not differ between patients and normals
(Fig. 4C). The notched boxes broadly overlay, as do thevalues overlapped (53 vs. 59 and 46 vs. 51, patient vs.
Asplin et al: Reduced crystallization inhibition1512
Fig. 5. ULM-SS distance vs. CaOx crystal
growth inhibition. (A) Values for CaP show
normal results (s) clustered in a small
85% nonparametric region of containment,
whereas patient data (d) are spread out over
the entire graph surface. Five patients were in-
distinguishable from normal. The rest show-
ed an abnormal ULM-SS distance or reduced
growth inhibition or both. (B) Values for
CaOx were the same in general outlines, but
normals differed from patients less com-
pletely. Note the single outlier normal point
enclosed by its own nonparametric envelope.
Growth inhibition was performed using 16
mg/ml of dialyzed urine proteins.
distributions of points and the frequency distributions these are taken only in the stone-forming direction, high
growth rate as percentage control (rightward, x axis) andthat represent them. By t-tests, the P value for the differ-
ence is not significant (mean values 38 vs. 34%, P 5 low ULM-SS distance (downward direction, y axis).
Having analyzed how individual tests differ in average0.27). These data were taken at 100 mg/ml. Values at 50
mg/ml (data not shown) were also not different (54 vs. result between patients and normals and also having
inspected the primary discriminators, one might ask how51% control, P 5 0.48). Higher and lower concentrations
were not studied here, as prior research has shown that abnormal test results, that is, results that are uncommon
among normal subjects, occur and cluster within individ-this range of urine proteins gives the most dynamic re-
sponse of adhesion. ual patients. To do this, we have considered the distribu-
tions of abnormal and normal values for each test (Fig.Having analyzed all five individual measures of inhibi-
tion (ULM CaP, ULM CaOx, growth, aggregation, and 6). The figure makes clear how deviant from the normals
are patient values for growth and for the ULM to SScell adhesion) and all individual primary urine measure-
ments (Fig. 1) taken one by one, we assessed their rela- distance (Fig. 6 A and B), making it no surprise that
these two measurements predominate in their separationtive contributions to the discrimination of patient from
normal using standard multivariate discriminant analy- of patients from normals. For the CaOx ULM to SS
difference (Fig. 6C), the almost bifurcate distribution ofsis. From the entire set of values, only growth inhibition
and the ULM to SS distance for CaP entered as signifi- points, a reflection of the tram tracking of Figure 2 is
evident. The small difference of aggregation inhibitioncant discriminators (F values 6.7 and 12.6 for the ULM
to SS difference and growth, respectively). The classifi- between normals and patients, favoring patients, and the
nonsignificant difference for crystal adhesion are alsocation was 16 out of 17 correct for normals, and 11 out
of 17 for patients, overall 79%. No other measurements evident as population characteristics. We calculated 1.5
and 2 units of deviation from the normal mean for theadded power nor had a significant F value if forced into
the equation. ULM to SS differences and for the growth, aggregation,
and adhesion inhibition results. For the CaOx ULM toGiven their pre-eminence, we plotted the ULM to SS
difference for CaP against CaOx crystal growth inhibi- SS difference, there is a clear outlier among normals,
also visible on Figure 4 as a single point within its owntion for the 17 patients and 17 normals (Fig. 5A). The
normals are enclosed in a small 85% nonparametric containment boundary. Because we are interested in the
main normal tendency, we calculated the standard devia-boundary in which only five of the patients reside. The
other patients are spread out over the whole graph sur- tion and the means without this point for this one test.
Patient data are easily identified as 1.5 and 2 sd outliersface. By comparison, a corresponding plot for CaOx (Fig.
5C) resembles that of CaP. However, the packing of the on the five panels.
For each patient, we accumulated whatever defectsnormals is less intense, and more of the patients are
within or at the boundaries of the 85% containment area were present and classified each along all five abnormal
parameters (Fig. 7) using a standard Venn Diagram.for normals. This latter overlap of patients with normals
is the reason that the ULM to SS difference for CaOx Fifteen of the 17 patients were abnormal and are plotted
on the left hand panel of the figure. It is clear that jointwas not as effective in the discrimination between pa-
tients and normals as was the difference for CaP. For defects of growth and the ULM to SS difference for
CaP predominate here as in the general analysis of the1.5 and 2 sd from the normal, the means are erected on
each graph as dashed lines. Because of interest here, populations. When the normals were classified in the
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Fig. 6. Frequency distributions of all five tests of inhibition. Values for patients (d) and normals (s) deviate greatly for growth inhibition (A)
and the ULM to SS distance for CaP (B). For the ULM to SS distance for CaOx (C), approximately half of the patient points differ dramatically
from normals, the others being indistinguishable. Patients and normals differ only slightly for cell adhesion and aggregation inhibitions (D and
E). Lines show 1.5 and 2 sd displacements from the normal means. In the case of the ULM to SS distance, the mean and sd was calculated
omitting the single outlier point at 0. Growth inhibition data were obtained using 16 mg/ml of dialyzed urine protein. Aggregation inhibition data
were obtained using 0.006% of the 24-hour excretion of urine protein.
same manner, essentially culling out their outlier points, assays are, perhaps indirectly, a reflection of some rather
common and therefore potentially important underlyingfour were abnormal, mainly with single defects.
disorder of inhibition. Routine urine chemistries, by con-
trast, showed great overlap, with only calcium excretion
DISCUSSION being statistically different by nonparametric testing.
Among the many assays and measurements used for The mild hypercalciuria and lack of a low mean urine
this panel of highly selected patients and well-matched citrate compared with normals are typical of what we
normals, only seeded CaOx crystal growth inhibition and have described before in large populations [26]. CaOx
the CaP ULM to SS distance distinguished the two. An and CaP SS among men is not higher in patients than
analysis of individual patients shows a general trend to- normals [28, 36], as we show, once again, in this study.
ward multiple abnormal values, predominantly in these Overall, the measurements of inhibition appear to be a
two measurements, but also to an appreciable extent in more robust differentiator of stone-forming men from
the ULM to SS distance for CaOx. Measurements of normal men than urine analytes or SS measurements.
aggregation, cell adhesion, and citrate—a small molecu- We long ago and with a different assay showed a simi-
lar weight urine inhibitor—did not show any departures lar pattern for growth inhibition, although the controls
from normal among patients. Of most interest is that all were not so well matched [13], but in our more recent
but 2 of 17 men with stones were abnormal in one or study of patients chosen for extremes of stone disease
[14], we did not find this same effect. Others, using assaysmore of the inhibition assays, a fact that suggests these
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Fig. 7. Classification of individual patients by
five tests of inhibition. Fifteen of the 17 pa-
tients were abnormal in at least one test (left
panel) by 2 sd (closed symbols) or 1.5 sd (open
symbols) in the joint regions when 1.5 sd for
both measurements and closed but touching
the border of a test region when 2 sd abnormal
in the region it is centered in and 1.5 sd abnor-
mal in the region it touches at the border. By
comparison, only four normals had even one
outlier point (right panel). Triangles denote 2
sd abnormalities of adhesion and whatever
tests the point is situated in; the geometry of
the diagram makes a proper overlap in these
cases impossible.
in which the effects of growth combine with those of this reason, strongly favor additional studies of the ULM
SS interplay. However, at least in comparison to growthnucleation, have found that patient urine is less effective
than normal [37]. Tiselius et al, using a growth-inhibition inhibition, ULM and SS are not clear demarcators of
patients from normal so much as a clue—however enig-assay similar to the one we used in prior studies [13, 15],
found growth inhibition to be reduced in male stone matic—to some underlying abnormality of ULM and SS
regulation in patients. Of the two ULM to SS distances,formers compared with nonstone formers. Interestingly,
they found no growth inhibition defect in women stone that for CaP was slightly more often abnormal among
the patients than that for CaOx, which raises the questionformers, supporting our original premise to study the
genders separately. Overall, the weight of evidence and of possible interactions between these two phases. Most
CaOx stones contain some CaP [38], and CaP phasesthis study point to growth inhibition as a very promising
assay to follow in clinical and research studies for the are efficient heterogeneous nucleators of CaOx [39].
Randall’s plaques [40, 41] are anchored CaP deposits onfuture.
Our 1980 study used whole urine added to a growth the surfaces of papillary epithelium and have been often
mentioned as seeding and attachment sites for CaOxassay of a different kind than used here [13]. Our current
study used urine dialyzed against buffer (discussed in stones [40, 42]. Perhaps in our work we have uncovered
yet another aspect of the CaP CaOx relationship, in thatthe Methods section). Our recent study of accelerated
stone patients dialyzed urine against water [14]. We sus- our work predicts a more ready crystallization of CaP
among CaOx stone formers than among controls.pect that the water dialysis affected samples such as to
erase differences between patients and normals, for in There was a strong relationship of urine citrate con-
centration to ULM of CaP and CaOx. Most of the crystalthat study, we found none. To test this, we dialyzed one
sample of urine, in this study, against water, and found inhibition activity of citrate is due to complexation of
calcium, thus lowering the ion activity of calcium in thethat inhibition fell (Methods section). Perhaps this is not
the main or only reason for the discrepancies, as patient urine. Nicar, Hill, and Pak have studied the effect of citrate
on the ULM of CaOx in synthetic solutions [43]. By ad-selection of the recent accelerated nephrolithiasis study
was very unusual and differed greatly from our old [13] justing both the total and ionized concentrations of cal-
cium and citrate, the authors were able to show that mostand current work. Either way, growth inhibition, as per-
formed here, is and was in the past a very robust marker of the change in ULM from citrate was due to calcium
complexation, but that there was an independent directof stone formers, which suggests that reduced growth inhi-
bition gauges something that is important in stone patho- increase of the ULM of CaOx by citrate. The effect on
CaP ULM was not studied. Citrate could also effect thegenesis and, therefore, something worth discovering.
Measures of ULM, by us and others [18], continue to ULM by increasing the inhibitory activity of urine macro-
molecules, as has already been shown for aggregationshow differences between patients and normals, such as
we show here, but differences that are hard to pin down inhibition [22, 44]. However, it is clear from our work that
citrate is not the only determinant of ULM, as patientsand that seem related to the interplay of SS and ULM
more than to ULM in isolation. How and why ULM and differ from controls despite comparable urine citrate lev-
els. Thus, there must be other significant determinantsSS vary with one another is a mystery, but the phenome-
non is robust, as we have found it in rats and a separate of ULM that are quantitatively different in stone formers
and normals. In our particular experiment, increasinggroup of patients [20] that does not overlap with this one.
One can easily imagine that low ULM in relationship to citrate correlated with higher ULM, whereas increasing
citrate did not necessarily reduce but did not increase SS.SS could be crucial in allowing stones to form and, for
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Because ULM correlates positively with SS, the rising impossible to maintain that nothing can be learned from
diluted and processed urine products. Given the assayULM with rising citrate molarity cannot reasonably be
ascribed to the effect of citrate to lower free ion concen- points to patients, it is not a bad compass for finding the
tration for calcium and therefore SS. molecules that contribute to stone risk, and thus perhaps
We and others have described the reduced inhibition improving metabolic assessment and medical manage-
of CaOx crystal aggregation by urine proteins of stone ment of renal stone disease.
formers versus normals, whereas in this study the results
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